Estrogenic or Antiestrogenic Therapies for Multiple Myeloma? - Normandie Université Access content directly
Journal Articles Molecular Cancer Year : 2007

Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?


Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and antiestrogenic compounds are very promising drugs for the treatment of MM. Indeed, they inhibit cell proliferation in vitro. They block cell cycle and/or induce apoptosis even in drug-resistant MM cells but not normal B cells. They interfere with survival pathways often deregulated in myelomas. They cooperate with conventional drugs to enhance apoptosis or to overcome resistance. In vivo, they act also on tumoral angiogenesis in xenograft models. As a whole, they possess all the criteria which render them attractive for a new therapeutic strategy. Importantly, they are well-tolerated at the doses tested in vitro or in vivo, encouraging the rapid onset of critical trials.
Fichier principal
Vignette du fichier
b_sola.pdf (434.15 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-01762023 , version 1 (24-07-2019)





Brigitte Sola, Jack-Michel Renoir. Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?. Molecular Cancer, 2007, 6 (1), pp.59. ⟨10.1186/1476-4598-6-59⟩. ⟨hal-01762023⟩
31 View
58 Download



Gmail Facebook Twitter LinkedIn More